Protalix Rises Most in Week, Narrows Gap With U.S. Stock

Protalix BioTherapeutics Inc., a Carmiel-based biotechnology company, jumped the most in more than a week, narrowing the gap with its U.S.-traded shares.

The shares gained 6.5 percent, the most since Nov. 28, to 20.13 shekels, or the equivalent of $5.37, at 11:23 a.m. in Tel Aviv. Protalix closed at $5.39 yesterday in New York.

To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at

To contact the editor responsible for this story: Claudia Maedler at

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.